Cefaliv® Compared to Neosaldina® in the Treatment of Migraine Attacks

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
This study evaluates the non-inferiority of Cefaliv® compared to Neosaldina® in the treatment of migraine attack in two hundred and sixteen adults of both sexes with age between eighteen and sixty five years old. The first Half of participants will receive Cefaliv®, the other half will receive Neosaldina®.
Epistemonikos ID: 22b94ff0d3c6c98872df356c97deaf3192cd6392
First added on: May 12, 2024